Medical/Pharmaceuticals

VSure and HEYDOC Health Introduce CareConnect Suite, Transforming SME Protection and Digital Healthcare in Malaysia

KUALA LUMPUR, Malaysia, Dec. 9, 2025 /PRNewswire/ -- In a move that reflects the shifting expectations ofMalaysia's modern workforce, VSure Group and virtual healthcare provider HEYDOC Health have jointly launchedCareConnect Suite , a new digital ecosystem aimed at closing long-standing gaps in em...

2025-12-09 15:58 992

Sweden Recommends: A Dose of Northern Lights Therapy

STOCKHOLM, Dec. 9, 2025 /PRNewswire/ -- As the world's first country to be prescribed for its health benefits,Sweden is now shining a light on one of its most awe-inducing wellness experiences. Aurora Borealis – the original arctic light therapy...

2025-12-09 15:53 709

Greenyn Biotechnology Launches Insumate® mcIRBP-19 Bitter Melon Peptide, Targeting the Billion-Dollar Health Supplement Market

TAICHUNG, Dec. 9, 2025 /PRNewswire/ -- Backed by New Medical Association Certification, Insumate® Becomes the Only Bitter Melon Peptide Globally Recognized by FDA-NDI, SNQ, and the Taiwan Complementary Medicine Society (TCMS). As global demand for scientifically validated metabolic health ingred...

2025-12-09 10:30 1101

Therme Group acquires full Thermengruppe Josef Wund portfolio through Therme Horizon, integrating all four Wund-origin destinations into its global platform

MUNICH, Dec. 9, 2025 /PRNewswire/ -- Therme Group, a leading developer, owner and operator shaping the future of wellbeing infrastructure, today announced the acquisition of three thermal wellbeing destinations — Euskirchen, Sinsheim, and Titisee-Neustadt — from the Josef Wund Foundation. The tra...

2025-12-09 09:00 1001

Inheritance + Innovation + Development: The "Co-development" Path of Hakka Medicine and Traditional Chinese Medicine

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- From November 23 to 25, the Seventh World Hakka Entrepreneurs Convention was held in Meizhou,Guangdong. The conference, with the theme of "Gather Global Hakka Entrepreneurs • Facilitate High-Quality Development," upheld the principles of "openness, innovati...

2025-12-09 08:00 914

EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide

PROVIDENCE, R.I., Dec. 9, 2025 /PRNewswire/ -- EpiVax, Inc. , with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publ...

2025-12-09 03:11 970

Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

* In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early stage breast cancer. FLORENCE, Italy and NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Menarini Gro...

2025-12-09 03:05 1180

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement – – Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes – – Favorable safety profile with no treatment-related serious adverse e...

2025-12-08 22:22 969

PT Fapon and PT Bio Farma Forge Strategic Partnership to Advance IVD Localization and Innovation in Indonesia

DONGGUAN, China, Dec. 8, 2025 /PRNewswire/ -- PT Fapon Bioindustries Indonesia (referred to as "PT Fapon") and the Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) (referred to as "Bio Farma") officially signed a cooperation agreement at Fapon's headquarters inDongg...

2025-12-08 20:47 795

Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions

* Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases. * These awards across several geographies recognize the progress represented by Voranigo® for patients living with glioma. SURESNES, France, De...

2025-12-08 20:24 933

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight

-  ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. -  ASC30 titrated weekly to target dose demonstrated approximately one-half the rate of vomiting observed w...

2025-12-08 17:40 1100

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

* Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1 * Holistic benefit: secondary endpoints showed significant and clinically meaningful improvements ...

2025-12-08 15:25 707

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

TOKYO, Dec. 8, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximatelyJPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as monkeypox2). Mpox is a viral infectious disease that h...

2025-12-08 09:00 882

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- ChemLex , a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory inSingapore, alongside the close of aUSD 45 million funding round led by Granite Asia

2025-12-08 08:00 1221

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare pro...

2025-12-08 08:00 938

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate can...

2025-12-08 06:08 764

/C O R R E C T I O N -- Seegene Inc./

In the news release, "Seegene Establishes French Subsidiary to Expand European Footprint", issued05-Dec-2025 by Seegene Inc. over PR Newswire, we are advised by the company that the first sub-headline should read "France becomes Seegene's eighth overseas sales subsidiary and third inEurope, follo...

2025-12-06 00:00 2547

AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer

-       Ovarian cancer remains an unmet medical need, and experts call for new strategies to define and treat platinum resistance in patients with advanced ovarian cancer[1],[2],[3] SINGAPORE, Dec. 5, 2025 /PRNewswire/ -- At an AbbVie-sponsored symposium at the ESMO Asia Congress 2025, experts g...

2025-12-05 16:00 918

Agilent and Monash University Malaysia Mark 15-Year Partnership with New BioDiscovery Hub to Drive Regional Biotech Innovation

Collaboration aimed at accelerating R&D in both small- and large-molecule analysis and building high-impact capabilities in fast-growing Asian markets KUALA LUMPUR, Malaysia, Dec. 5, 2025 /PRNewswire/ -- Agilent Technologies Inc.  (NYSE: A) announced the expansion of the...

2025-12-05 09:30 1942

Renuka Iyer, MD, Named New Chief Medical Officer for National Comprehensive Cancer Network (NCCN)

Acclaimed oncologist from Roswell Park Comprehensive Cancer Center to help lead nonprofit responsible for gold standard guidelines that define and advance cancer care worldwide. PLYMOUTH MEETING, Pa., Dec. 4, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of ...

2025-12-04 21:04 1050
123456 ... 397

Week's Top Stories